Vidaza (azacitidine): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Vidaza 25 mg/ml powder for suspension for injection

Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

• intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),

• chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,

• acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,

• AML with >30% marrow blasts according to the WHO classification.


Route of administration: Injectable
Molecule: azacitidine

Patients' opinions on Vidaza

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.